Clinical trials: Risperidone, completed
Schizophrenia, Psychosis
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
The goal of this observational study is to learn about how long-acting injectable antipsychotic (LAIA) medications are affected by the changes that take place in the body during pregnancy, and how much an unborn baby is exposed…
- Conditions
- Schizophrenia, Psychosis, Mania, Pregnancy
- Trial name
- LAMP (NCT05766007)
- Where
- 6 sites in Nigeria
- Volunteers
- 168 people
- Sponsor
- University of Liverpool
Schizophrenia, Psychotic Disorders
RiSPECT: Risperdal Safety Protocol Evaluation Consta Treatment, a Post Authorization Safety Survey to Obtain Information on the Safety and Efficacy of Risperidone When Used in Routine Clinical Practice
The purpose of this research study is to gather information on the safety and efficacy of risperidone when used in routine clinical practice.
- Conditions
- Schizophrenia, Psychotic Disorders, Schizoaffective Disorder
- Trial name
- NCT00458367
- Testing
- Open label risperidone long acting injectable
- Volunteers
- 5,296 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Schizophrenia, Psychotic Disorders
CAFE Comparison of Atypicals in First Episode of Psychosis
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day)…
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Trial name
- NCT00034892
- Testing
- Olanzapine, risperidone
- Where
- 26 sites in United States, Canada
- Sponsor
- AstraZeneca
Schizophrenia, Schizoaffective Disorder
Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder
A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder
- Trial name
- NCT00061802
- Testing
- risperidone, quetiapine
- Where
- 13 sites in United States, India and 1 more
- Volunteers
- 225 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Antipyretics Toxicity
Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment
Objective: Hyperprolactinemia(HPRL) which can result in a series of prolactin-related symptoms is a frequent adverse effect of antipsychotics.
- Conditions
- Schizophrenia, Antipyretics Toxicity, Prolactin Excess
- Trial name
- NCT04002258
- Testing
- Antipsychotic
- Where
- China
- Volunteers
- 10,363 people
- Sponsor
- Shanghai Mental Health Center
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Bipolar Disorder
Cost- Effectiveness and Quality of Life Assessment in Mood Disorder
To evaluate the effectiveness of three systematic interventions for Bipolar Disorder (BD) mixed episodes using medications available in the Brazilian Public Healthcare System (SUS), and assessment of the quality of life of these…
- Trial name
- NCT02870283
- Testing
- Lithium, Valproic Acid, Carbamazepine
- Volunteers
- 107 people
- Sponsor
- Federal University of Rio Grande do Sul
Schizophrenia, Schizoaffective Disorder
Study to Evaluate the Pharmacokinetics (PK) and Safety/Tolerability of Long-Acting Oral LYN-005
Lyndra Therapeutics, Inc. is developing LYN-005, a long-acting oral (LAO) capsule (LYNX™ dosage form) of risperidone. This pivotal study (LYN-005-C-301) will evaluate the PK as well as safety and tolerability of multiple…
- Trial name
- NCT05779241
- Testing
- LYN-005, Risperidone
- Where
- 5 sites in United States
- Volunteers
- 83 people
- Sponsor
- Lyndra Inc.
Healthy
Bioavailability Study of Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited Under Fasting Conditions
The purpose of this study was to assess the single-dose relative bioavailability study of 1 mg risperidone orally disintegrating tablets and (Risperdal M-TAB) under fasting conditions.
- Trial name
- NCT01155921
- Testing
- Risperidone Orally Disintegrating Tablets
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Schizophrenia, Schizoaffective Disorder
A Long-term Safety Study for Long-acting Injectable Risperidone in Schizophrenia or Schizoaffective Disorder Patients.
The purpose of this study is to document the long-term safety of 25, 37.5, or 50 mg long-acting injectable risperidone given via injection to the gluteal muscle every 2 weeks to subjects with schizophrenia or schizoaffective…
- Trial name
- NCT00495118
- Testing
- risperidone
- Volunteers
- 314 people
- Sponsor
- Janssen, LP
Schizophrenia
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
This is a single ascending dose phase 1 study to evaluate the pharmacokinetics (PK), safety, and tolerability of a single intramuscular (IM) injection of quarterly Risperidone (QUAR) for different formulations and dose strengths…
- Trial name
- QUARTZ (NCT06276361)
- Testing
- Oral risperidone; QUAR F1/2, Dose 1 - Gluteal, Oral risperidone; QUAR F1/2, Dose 2 - Gluteal, Oral risperidone; QUAR F1/2, Dose 3 - Gluteal
- Where
- Jordan
- Volunteers
- 58 people
- Sponsor
- Rovi Pharmaceuticals Laboratories
Post-Traumatic Stress Disorder
Risperidone Augmentation for PTSD
The purpose of this study is to (1) compare the response of civilians with Posttraumatic Stress Disorder(PTSD) currently receiving sertraline without an optimal response to risperidone augmentation vs.
- Trial name
- NCT00215241
- Testing
- sertraline and risperidone
- Where
- 2 sites in United States
- Volunteers
- 80 people
- Sponsor
- Duke University
Schizophrenia, Schizophreniform Disorder
Omega-3 Dietary Supplements in Schizophrenia
This 16-week placebo-control study looks to investigate whether patients with schizophrenia for two years or less may benefit from omega-3 supplements.
- Conditions
- Schizophrenia, Schizophreniform Disorder, Schizoaffective Disorder, Bipolar Disorder
- Trial name
- NCT01786239
- Testing
- Risperidone, Omega-3 capsules
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Delbert Robinson
Schizophrenia
Investigate Risperidone for the Treatment of Schizophrenia in Adolescents
A clinical study to evaluate the efficacy, safety and tolerability of two dose ranges of risperidone (1 to 3 mg/day, and 4 to 6 mg/day) versus placebo (an inactive substance like a sugar pill) in adolescents (aged 13 to 17 years)…
- Trial name
- NCT00088075
- Testing
- Risperidone
- Volunteers
- 160 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Bipolar Disorders, Manic Episode
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder
The purpose of the study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo during 3 weeks of treatment of mania in patients with Bipolar I Disorder who are suffering a manic…
- Trial name
- NCT00257075
- Testing
- Risperidone, oral tablets
- Volunteers
- 267 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Antipsychotics and Neuroleptics Toxicity
Synergistic Effect of Vitamin E & D in Reducing Risk of Effects Associated With Atypical Anti-psychotics
Atypical antipsychotic drugs are commonly used to treat psychiatric illnesses but they are significantly associated with side effects including acute dystonia, akathisia, parkinsonism (rigidity and tremor), tardive dyskinesia…
- Trial name
- NCT06200584
- Testing
- Risperidone, Olanzapine, Quetiapine
- Where
- Pakistan
- Volunteers
- 140 people
- Sponsor
- Dr Rabia Arshad
Methamphetamine Dependence
A Trial of Long-Acting Injectable Risperidone in the Treatment of Methamphetamine Dependence
Objective of the Project. -Methamphetamine (MA) use is growing to epidemic proportions and existing treatments for MA dependence demonstrate sub-optimal efficacy.
- Trial name
- NCT00284206
- Testing
- long-acting injectable risperidone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Seattle Institute for Biomedical and Clinical Research
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia
A Long Term Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia
The purpose of this study is to document the long term safety of a long-acting injectable formulation of risperidone in the treatment of patients with schizophrenia who have previously been treated with long-acting risperidone.
- Trial name
- NCT00236587
- Testing
- risperidone
- Volunteers
- 100 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Learning Disorders, Child Behavior Disorders
A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children
The purpose of this study is to assess whether risperidone (an antipsychotic medication) is safe and effective in treating behaviour disorder in learning disabled children, which does not improve with psychological therapy.
- Trial name
- NCT00254930
- Testing
- risperidone
- Volunteers
- 19 people
- Sponsor
- Janssen-Cilag Ltd.